Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

146.22B

Market cap146.22B

Price-Earnings ratio

306.95

Price-Earnings ratio306.95

Dividend yield

2.62%

Dividend yield2.62%

Average volume

10.36M

Average volume10.36M

High today

$118.42

High today$118.42

Low today

$114.79

Low today$114.79

Open price

$115.65

Open price$115.65

Volume

14.41M

Volume14.41M

52 Week high

$118.42

52 Week high$118.42

52 Week low

$62.07

52 Week low$62.07

GILD News

Simply Wall St 4d

Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates

As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly assessing opportunities that may arise fro...

TipRanks 5d

Gilead price target raised to $132 from $115 at Oppenheimer

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that with Gilead share...

Simply Wall St 5d

Gilead Sciences Full Year 2024 Earnings: Beats Expectations

Gilead Sciences ( ) Full Year 2024 Results Key Financial Results Revenue: US$28.8b (up 6.0% from FY 2023). Net income: US$480.0m (down 92% from FY 2023). Pr...

Analyst ratings

64%

of 33 ratings

Buy

63.6%

Hold

33.3%

Sell